Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) FCF Margin (2016 - 2025)

Coherus Oncology (CHRS) has disclosed FCF Margin for 12 consecutive years, with 220.36% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 59031.0% to 220.36% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 786.76% through Dec 2025, up 89.0% year-over-year, with the annual reading at 786.76% for FY2025, 89.0% up from the prior year.
  • FCF Margin hit 220.36% in Q4 2025 for Coherus Oncology, up from 400.48% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 6111.66% in Q1 2024 to a low of 1024.72% in Q3 2024.
  • Historically, FCF Margin has averaged 438.14% across 5 years, with a median of 72.38% in 2021.
  • Biggest five-year swings in FCF Margin: surged 632402bps in 2024 and later plummeted -651362bps in 2025.
  • Year by year, FCF Margin stood at 71.95% in 2021, then plummeted by -207bps to 220.59% in 2022, then surged by 94bps to 14.17% in 2023, then surged by 2710bps to 369.95% in 2024, then plummeted by -160bps to 220.36% in 2025.
  • Business Quant data shows FCF Margin for CHRS at 220.36% in Q4 2025, 400.48% in Q3 2025, and 4259.49% in Q2 2025.